Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma.

MLA

Bajetta, Emilio, et al. “Activity of a Three-Drug Combination Including Cisplatin (CLOVER Regimen) for Poorly Differentiated Neuroendocrine Carcinoma.” Anticancer Research, vol. 34, no. 10, Oct. 2014, pp. 5657–60. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=25275070&authtype=sso&custid=ns315887.

APA

Bajetta, E., Catena, L., Biondani, P., Pusceddu, S., Valente, M., Bianco, N., & Novelli, E. (2014). Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma. Anticancer Research, 34(10), 5657–5660.

Chicago

Bajetta, Emilio, Laura Catena, Pamela Biondani, Sara Pusceddu, Monica Valente, Nadia Bianco, and Eugenio Novelli. 2014. “Activity of a Three-Drug Combination Including Cisplatin (CLOVER Regimen) for Poorly Differentiated Neuroendocrine Carcinoma.” Anticancer Research 34 (10): 5657–60. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=25275070&authtype=sso&custid=ns315887.